ArticleBMC public health2026
Epidemiology of Neisseria gonorrhoeae in Jordan: prevalence, incidence, and clearance from a national laboratory dataset, 2014-2025.
Article in BMC public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundGonorrhea is a global public health priority due to substantial morbidity, sustained transmission, and increasing antimicrobial resistance; however, its epidemiology in Jordan and other settings with limited surveillance and research, such as in the Middle East and North Africa, remains inadequately characterized.
methodsData from 8,779 individuals aged ≥ 15 years tested for current Neisseria gonorrhoeae (NG) infection at Biolab Diagnostic Laboratories in Jordan between 2014 and 2025 were analyzed. A cross-sectional design was used to estimate prevalence, assess temporal trends, and identify factors associated with infection among all 8,779 individuals. Retrospective cohort designs were used to assess incidence among 784 individuals and, exploratorily, clearance among 5 individuals with repeat testing.
resultsNG prevalence, defined as ever having a NAAT-positive test, was 0.4% (95% CI: 0.2-0.5%) overall and 0.1% (95% CI: 0.0-0.2%) among individuals tested for visa-related requirements. Corresponding point prevalence, based on one randomly selected test per individual, was 0.3% (95% CI: 0.2-0.5%) and 0.1% (95% CI: 0.0-0.2%), respectively. NG positivity was substantially higher in clinically motivated testing compared with visa-related testing and among individuals with more frequent testing. No consistent patterns were observed by age, sex, or governorate, and there was no evidence of a temporal decline. In the retrospective cohort, three incident infections were identified over 1,167 person-years of follow-up, yielding a cumulative incidence of 0.49% (95% CI: 0.16-1.53%) after two years of follow-up and an incidence rate of 2.57 per 1,000 person-years (95% CI: 0.83-7.97). In exploratory analysis, nearly all individuals with follow-up after a positive test had a subsequent negative result within 10 days.
conclusionsObserved NG prevalence and incidence rate in Jordan were low. However, high positivity in clinically motivated testing contexts and the absence of a temporal decline indicate ongoing transmission that requires control. Strengthening surveillance, expanding targeted testing and treatment among higher-risk populations, and integrating NG antimicrobial resistance monitoring are needed to inform prevention and control efforts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.